Innovators in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies have joined TMC's Accelerator for Cancer Therapeutics. Photo courtesy TMC.

Texas Medical Center Innovation has named more than 50 health care innovators to the fifth cohort of its Accelerator for Cancer Therapeutics (ACT).

The group specializes in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies, according to a statement from TMC.

During the nine-month ACT program, participants will enjoy access to a network of mentors, grant-writing support, chemistry resources, and the entrepreneur-in-residence program. The program is designed to equip participants with the ability to secure investments, develop partnerships, and advance the commercialization of cancer therapeutics in Texas.

“With over 35 million new cancer cases predicted by 2050, the urgency to develop safer, more effective, and personalized treatments cannot be overstated,” Tom Luby, chief innovation officer at Texas Medical Center, said in a news release.

Members of the new cohort are:

  • Alexandre Reuben, Kunal Rai, Dr. Cassian Yee, Dr. Wantong Yao, Dr. Haoqiang Ying, Xiling Shen, and Zhao Chen, all of the University of Texas MD Anderson Cancer Center
  • Dr. Andre Catic and Dr. Martin M. Matzuk, both of the Baylor College of Medicine
  • Cynthia Hu and Zhiqiang An, both of UTHealth Houston
  • Christopher Powala, Aaron Sato, and Mark de Souza, all of ARespo Biopharma
  • Daniel Romo, Dr. Susan Bates, and Ken Hull, all of Baylor University
  • Eugene Sa & Minseok Kim, both of CTCELLS
  • Gomika Udugamasooriya and Nathaniel Dawkins, both of the University of Houston
  • Dr. Hector Alila of Remunity Therapeutics
  • Iosif Gershteyn and Victor Goldmacher, both of ImmuVia
  • João Seixas, Pedro Cal, and Gonçalo Bernardes, all of TargTex
  • Ken Hsu and Yelena Wetherill, both of the University of Texas at Austin
  • Luis Martin and Dr. Alberto Ocaña, both of C-Therapeutics
  • Dr. Lynda Chin, Dr. Keith Flaherty, Dr. Padmanee Sharma, James Allison, and Ronan O’Hagan, all of Project Crest/Apricity Health
  • Michael Coleman and Shaker Reddy, both of Metaclipse Therapeutics
  • Robert Skiff and Norman Packard, both of 3582.ai
  • Rolf Brekken, Uttam Tambar, Ping Mu, Su Deng, Melanie Rodriguez, and Alexander Busse, all of UT Southwestern Medical Center
  • Ryan Swoboda and Maria Teresa Sabrina Bertilaccio, both of NAVAN Technologies
  • Shu-Hsia Chen and Ping-Ying Pan, both of Houston Methodist
  • Thomas Kim, Philipp Mews, and Eyal Gottlieb, all of ReEngage Therapeutics
The ACT launched in 2021 and has had 77 researchers and companies participate. The group has collectively secured more than $202 million in funding from the NIH, CPRIT and venture capital, according to TMC.
The University of Texas MD Anderson Cancer Center was recognized for advancements in electronic functionality, AI and robotics. Photo via mdanderson.org

Houston hospital named among smartest in the nation

hi, tech

Houston hospitals are chock-full of smart people. But they’re also equipped with lots of “smart” technology. In fact, five local hospitals appear on Newsweek’s new list of the world’s best “smart” hospitals.

To compile the list, Newsweek teamed up with data provider Statista to rank the world’s top 330 hospitals for the use of smart technology. The ranking factors were electronic functionality, telemedicine, digital imaging, artificial intelligence (AI), and robotics.

The highest-ranked Houston hospital is the University of Texas MD Anderson Cancer Center, appearing at No. 6. The hospital was recognized for advancements in electronic functionality, AI and robotics.

“MD Anderson has a significant opportunity and a responsibility to our many stakeholders to create a digital ecosystem that promotes collaboration and advances scientific discovery to enhance patient outcomes,” David Jaffray, the cancer center’s chief technology and digital officer, said in a 2021 news release.

“Through our ongoing focus on enabling the use of new technologies to place quantitative data in context for our researchers,” Jaffray added, “we foster cutting-edge oncology data science to inform our cancer discovery research and to accelerate translation of our research findings into benefits for cancer patients.”

Ahead of MD Anderson on the list are:

  1. Mayo Clinic in Rochester, Minnesota.
  2. Cleveland Clinic in Cleveland.
  3. Massachusetts General Hospital in Boston.
  4. Johns Hopkins Hospital in Baltimore.
  5. Mount Sinai Hospital in New York City.

Other Houston hospitals on the list are:

  • Houston Methodist Hospital, No. 11.
  • Baylor St. Luke’s Medical Center, No. 105.
  • Texas Children’s Hospital, No. 197.
  • Memorial Hermann-Texas Medical Center, No. 266.
CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

The home of the Rice Owls is on top once again. Photo via Rice University

Rice University named top college in U.S. News' new rankings for 2025

top of class

Houston's own "Ivy League of the South" has come out on top as one of the best universities in the nation for 2025, according to U.S. News and World Report's just-released list of the Best Colleges for 2025.

Rice University claimed No. 1 in Texas, and ranked No. 18 nationally in a one-spot slip from last year's ranking. The private institution has a 98 percent first-year retention rate, and an "actual" graduation rate of 96 percent. Rice costs $60,709 in tuition and fees for students each year, and according to the school's profile, it has an acceptance rate of eight percent.

In April, Rice's Jesse H. Jones Graduate School of Business ranked No. 2 in U.S. News' ranking of the best graduate schools in Texas, with its entrepreneurship program tying for No. 8 nationally, and the part-time MBA program ranking No. 15 overall. Those rankings may change in the next few years once the school finishes its brand new facility for the business school.

Rice also fared similarly in Niche'slist of best colleges, in which it ranked No. 15 nationally. Forbes ranked the university No. 9 nationwide in its list of best colleges for the 2024-2025 school year, and Rice was bestowed an "Ivy League" status in Forbes' recent report on top public and private schools that churn out top graduates.

“We are delighted to see Rice University recognized as one of America’s producers of great talent. Rice has been a recruiting destination for employers for many years and that is because Rice students are adaptable, curious, bright, and are solution oriented,” Nicole Van Den Heuvel, executive director of the Center for Career Development, says in a news release from Rice.

In a glowing review of the university, one former business student said studying at Rice was a "transformative experience."

"Rice is the perfect blend of rigorous academics, strong athletics, and a nurturing and engaging social life," the reviewer wrote. "It's quite idyllic. Rice is known as a STEM school, but it has distinguished programs in humanities, social sciences, music and architecture too. Professors are top scholars in their fields and will know you by name. Students are well prepared academically, but are also collaborative and supportive."

Right behind Rice in the rankings is The University of Texas at Austin, which ranked No. 2 in Texas and No. 30 nationally. Just behind UT Austin is College Station's Texas A&M University, which placed No. 3 in the Texas rankings and No. 51 nationally.

The University of Houston maintained its No. 8 rank in the statewide comparison, but fell 11 spots down into No. 144 in the national rankings.

The University of St. Thomas ranked No. 9 in Texas, and moved up seven places to rank No. 209 in the U.S. for 2025.

U.S. News' top 10 best colleges in Texas in 2024 are:

  • No. 1 – Rice University, Houston
  • No. 2 – University of Texas at Austin
  • No. 3 – Texas A&M University, College Station
  • No. 4 – Baylor University, Waco
  • No. 5 – Southern Methodist University, Dallas
  • No. 6 – Texas Christian University, Fort Worth
  • No. 7 – The University of Texas at Dallas, Richardson
  • No. 8 – University of Houston
  • No. 9 – University of St. Thomas, Houston
  • No. 10 – Texas Tech University, Lubbock

The full rankings can be found on usnews.com.

------

This article originally ran on CultureMap.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

MD Anderson Cancer Center is still the best cancer-focused hospital in the U.S. and Texas. Photo by F. Carter Smith/courtesy of MD Anderson

Houston hospitals recognized as best in state, nation in annual report

better than all the rest

Houston’s University of Texas MD Anderson Cancer Center has retained its U.S. News & World Report crown as the best cancer hospital in the U.S.

In the same ranking, Houston Methodist Hospital once again came out on top as the best hospital in Texas. Last year, the hospital shared the top spot. Baylor St. Luke’s Medical Center ranked No. 4, followed by No. 5 Memorial Hermann Hospital.

The accolades appear in U.S. News2024-25 ranking of the country’s best hospitals. Each hospital also ranked among various specialties, such as orthopedics; cardiology, heart, and vascular surgery; cancer; and neurology and neurosurgery.

Since U.S. News introduced its annual hospital survey in 1990, MD Anderson has been ranked one of the two best U.S. hospitals for cancer care. It has maintained its No. 1 ranking for 10 consecutive years.

“At MD Anderson, our mission is clear: to end cancer,” Dr. Peter WT Pisters, president of MD Anderson, says in a news release. “This ranking reflects our relentless commitment to excellence in patient care, research, prevention, and education.”

MD Anderson also ranked highly in three specialties:

  • No. 2 for ear, nose, and throat.
  • No. 9 for urology.
  • No. 14 for gastroenterology and GI surgery.

“The consistent top national recognitions [that] MD Anderson receives for delivering compassionate, evidence-based care is a testament to our dedication to those we serve,” Pisters says.

Elsewhere at the Texas Medical Center, Houston Methodist Hospital was named the No. 1 hospital in Texas for the 13th year in a row. Also, it was lauded as one of the country’s 20 best hospitals for the eighth time.

Along with the general ranking, Houston Methodist Hospital scored high marks in 10 specialties. These include diabetes and endocrinology (No. 6), gastroenterology and GI surgery (No. 7), and pulmonology and lung surgery (No. 8).

Meanwhile, four Houston Methodist community hospitals ranked well in Texas:

  • Houston Methodist The Woodlands Hospital (No. 8).
  • Houston Methodist Sugar Land Hospital (No. 9).
  • Houston Methodist Baytown Hospital (tied at No. 18).
  • Houston Methodist Willowbrook Hospital (tied at No. 23).
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas startup's lunar lander aces moon touchdown with special delivery for NASA

Touchdown

A private lunar lander carrying a drill, vacuum and other experiments for NASA touched down on the moon Sunday, the latest in a string of companies looking to kickstart business on Earth's celestial neighbor ahead of astronaut missions.

Firefly Aerospace’s Blue Ghost lander descended from lunar orbit on autopilot, aiming for the slopes of an ancient volcanic dome in an impact basin on the moon’s northeastern edge of the near side.

Confirmation of successful touchdown came from the company's Mission Control outside Austin, Texas, following the action some 225,000 miles away.

“You all stuck the landing. We’re on the moon,” Firefly’s Will Coogan, chief engineer for the lander, reported.

An upright and stable landing makes Firefly — a startup founded a decade ago — the first private outfit to put a spacecraft on the moon without crashing or falling over. Even countries have faltered, with only five claiming success: Russia, the U.S., China, India and Japan.

A half hour after landing, Blue Ghost started to send back pictures from the surface, the first one a selfie somewhat obscured by the sun's glare. The second shot included the home planet, a blue dot glimmering in the blackness of space.

Two other companies’ landers are hot on Blue Ghost’s heels, with the next one expected to join it on the moon later this week.

Blue Ghost — named after a rare U.S. species of fireflies — had its size and shape going for it. The squat four-legged lander stands 6-foot-6-inch tall and 11 feet wide, providing extra stability, according to the company.

Launched in mid-January from Florida, the lander carried 10 experiments to the moon for NASA. The space agency paid $101 million for the delivery, plus $44 million for the science and tech on board. It’s the third mission under NASA’s commercial lunar delivery program, intended to ignite a lunar economy of competing private businesses while scouting around before astronauts show up later this decade.

Firefly’s Ray Allensworth said the lander skipped over hazards including boulders to land safely. Allensworth said the team continued to analyze the data to figure out the lander's exact position, but all indications suggest it landed within the 328-foot target zone in Mare Crisium.

The demos should get two weeks of run time, before lunar daytime ends and the lander shuts down.

It carried a vacuum to suck up moon dirt for analysis and a drill to measure temperature as deep as 10 feet below the surface. Also on board: a device for eliminating abrasive lunar dust — a scourge for NASA’s long-ago Apollo moonwalkers, who got it caked all over their spacesuits and equipment.

On its way to the moon, Blue Ghost beamed back exquisite pictures of the home planet. The lander continued to stun once in orbit around the moon, with detailed shots of the moon's gray pockmarked surface. At the same time, an on-board receiver tracked and acquired signals from the U.S. GPS and European Galileo constellations, an encouraging step forward in navigation for future explorers.

The landing set the stage for a fresh crush of visitors angling for a piece of lunar business.

Another lander — a tall and skinny 15-footer built and operated by Houston-based Intuitive Machines — is due to land on the moon Thursday. It’s aiming for the bottom of the moon, just 100 miles from the south pole. That’s closer to the pole than the company got last year with its first lander, which broke a leg and tipped over.

Despite the tumble, Intuitive Machines' lander put the U.S. back on the moon for the first time since NASA astronauts closed out the Apollo program in 1972.

A third lander from the Japanese company ispace is still three months from landing. It shared a rocket ride with Blue Ghost from Cape Canaveral on Jan. 15, taking a longer, windier route. Like Intuitive Machines, ispace is also attempting to land on the moon for the second time. Its first lander crashed in 2023.

The moon is littered with wreckage not only from ispace, but dozens of other failed attempts over the decades.

NASA wants to keep up a pace of two private lunar landers a year, realizing some missions will fail, said the space agency's top science officer Nicky Fox.

“It really does open up a whole new way for us to get more science to space and to the moon," Fox said.

Unlike NASA’s successful Apollo moon landings that had billions of dollars behind them and ace astronauts at the helm, private companies operate on a limited budget with robotic craft that must land on their own, said Firefly CEO Jason Kim.

Kim said everything went like clockwork.

“We got some moon dust on our boots," Kim said.

Houston startup Nap Bar pivots with VR and big plans for growth

power nap

Houston’s Khaliah Guillory takes a 30-minute nap every day. She says this is how she’s so productive.

The habit also led to the founding of her white-glove, eco-friendly rest sanctuary business, Nap Bar.

Guillory launched the luxury sleep suites company back in 2019 to offer a unique rest experience with artificial intelligence integration for working professionals, entrepreneurs and travelers who needed a place to rest, recharge and rejuvenate. The company was named a Houston Innovation Awards finalist last year.

She says naps are backed by science. And by her professional network, too.

“Once I polled and surveyed my friends, most of them said that they also took naps during their lunch break, whether it be in their office or in their car,” says Guillory, former vice president of marketing strategy at Wells Fargo. “Once they overwhelmingly agreed that they would absolutely use a dedicated place for them to take naps if I created it, I got to work, and Nap Bar was born.”

Simply put, Guillory has effectively made it acceptable and, yes, even cool for working adults to take naps.

“I played D1 basketball at the University of Central Florida and that’s really where I learned the art of a power nap and the benefits of it,” Guillory says. “And I just continued to nap throughout my corporate career. So, in November of 2018, I retired from corporate America … I just knew I had a higher calling to do something else.”

Guillory first opened up shop in Rice Village as a beta test for her novel nap idea and it took off. She soon forged strategic partnerships with organizations like UT Health, where Nap Bar provided much-needed naps to postpartum mothers.

“Nap Bar showed what the benefits of a good nap was, specifically to postpartum moms in terms of mental stressors, productivity, and things of that nature,” Guillory says.

In November 2019, Guillory moved Nap Bar to The Galleria and says the business produced revenue from day one. However, in March 2020, she was forced to shut us down due to the COVID-19 pandemic.

“I promised myself that I was not going back to corporate America, so I pivoted. I moved forward by creating a better sleep box, with a vegan pillow mist and soy-based candle. I also became a certified sleep coach. And I just kept pivoting from there, reinventing Nap Bar as a company,” she says.

One pivot included adding a virtual reality sleep experience, MetaSnooze.

“MetaSnooze is a really cool technology that offers sleep therapy and relaxation that I curated myself,” Guillory says. “Basically, the user puts on the VR headset, and it escapes them. They're transported to places all over the country. For example, they're sitting in serene environments all the while listening to these rhythmic beats that are designed to help them release and relax. Visualizations have been scientifically proven to improve one’s mental health and mental stressors.”

Guillory initially rolled out MetaSnooze in 2020 at events like South by Southwest and kept improving the experience and building her business. By February 2024, she was curating a wellness experience at The Grammy Awards.

“That was huge for us,” Guillory says. “Being able to get feedback from the celebrities, with a handful of them even inquiring where they could purchase the headset. They were excited about the future of Nap Bar, so that was really, really cool.”

The widespread interest in Nap Bar has Guillory thinking big. She aims to expand to 30 locations in three years.

“When I say that, it sounds ambitious,” says Guillory. “It is, but I come from the school of thought that if you shoot for 30 and you get 25, no one's going to shake their finger at you for doing that, right? It's really aiming towards this big, hairy, audacious goal. I learned that in corporate America. So, what we're looking to do now is raise money like crazy.”

Guillory says she’s now looking to scale the business by partnering with like-minded investors with experience in the wellness space.

She envisions locations at national and international airports, which she says offer ripe scenarios for patrons needing to recharge. Additionally, Guillory wants to build on her initial partnership with UT Health by going onsite to curate rest experiences for patients, caregivers, faculty, staff, nurses and doctors. Colleges also offer an opportunity for growth.

“We’ve done some really cool pop-ups with the University of Houston, where we brought the rest experience on campus,” Guillory says. “That means we bring a portable, full-size, organic mattress with disposable sheets, as well as our virtual reality experience.”

Nap Bar will also serve companies, office buildings, and even sports venues, according to Guillory.

“We can literally go any and everywhere,” she says. “Our collected data suggests that we’ve just got to go where sleepy people are so that they can get restorative sleep.”

From a pricing standpoint, Nap Bar’s model is a dollar a minute. Depending on where the client is, the pop-up experience is based on a day rate or a half-day rate, starting at $4,000.

Add-ons include a full-size organic mattress or hosting a masseuse or massage therapist onsite.

With the Grammys already under her belt, Guillory would like to see Nap Bar utilized at the 2028 Olympics and build partnerships with other virtual reality companies to bring its licensed MetaSnooze software to the masses.

She also sees opportunities in athletic treatment, sleep apnea, and insomnia.

“We have done several studies with proven results that MetaSnooze has reduced mental stressors and anxiety,” Guillory says. “I'm excited about what the future holds for MetaSnooze. It definitely is a game-changer … We will continue to innovate sleep or provide sleep resources and tools in a very innovative way.”